The EDIL3 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely used Huh-7 human hepatocellular carcinoma cell line. This heterogeneous pool contains cells with targeted disruption of the EDIL3 gene, creating a robust loss-of-function model that avoids clonal selection biases. The product is supplied as live polyclonal knockout cells, ready for downstream applications.
The parental Huh-7 cell line originates from a well-differentiated liver tumor and is extensively employed in hepatocarcinogenesis research and hepatitis C virus replication studies. Huh-7 cells retain characteristics of malignant hepatocytes, including rapid proliferation, anchorage-independent growth, and tumorigenicity in vivo, thereby providing a clinically relevant context for exploring liver cancer biology.
EDIL3 encodes DEL-1, a secreted glycoprotein that binds integrins ??v??3 and ??v??5 and phosphatidylserine. This interaction triggers FAK/Src activation, leading to PI3K/Akt and ERK1/2 phosphorylation, which promotes cell adhesion, migration, and survival. DEL-1 also inhibits LFA-1-dependent leukocyte adhesion, providing anti-inflammatory effects. EDIL3 expression is induced by TGF-??, hypoxia (HIF1??), and NF-??B, while downstream it upregulates VEGF and MMP-2/9, key mediators of angiogenesis and invasion.
In hepatocellular carcinoma, EDIL3 overexpression correlates with aggressive tumor behavior and metastatic dissemination. The polyclonal EDIL3 knockout Huh-7 cells offer a powerful genetic model to examine the contributions of DEL-1 to liver cancer cell migration, invasion, and angiogenesis. Disruption of EDIL3 is expected to dampen integrin-mediated FAK/Akt/ERK signaling and reduce the secretion of pro-angiogenic factors such as VEGF, thereby providing a platform to investigate key molecular events in HCC progression.
Researchers can utilize this knockout pool in Boyden chamber and Matrigel invasion assays to quantitatively measure migratory and invasive potential, respectively. Western blot analysis of phosphorylated FAK (Tyr397), Akt (Ser473), and ERK1/2 (Thr202/Tyr204) allows direct assessment of signaling pathway activity. Tube formation assays evaluate angiogenic capabilities, while immunofluorescence and ELISA enable visualization and quantification of DEL-1 localization and secretion. For immune interaction studies, the LFA-1-dependent leukocyte adhesion assay can be employed. These cells are also suitable for drug target validation and high-throughput screening campaigns. Please contact Ascent Research for additional technical information.
